These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11912142)

  • 1. Oncolytic reovirus against ovarian and colon cancer.
    Hirasawa K; Nishikawa SG; Norman KL; Alain T; Kossakowska A; Lee PW
    Cancer Res; 2002 Mar; 62(6):1696-701. PubMed ID: 11912142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
    Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
    Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
    Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA
    Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viral therapy for human pancreatic cancer cells by reovirus.
    Etoh T; Himeno Y; Matsumoto T; Aramaki M; Kawano K; Nishizono A; Kitano S
    Clin Cancer Res; 2003 Mar; 9(3):1218-23. PubMed ID: 12631628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain.
    Unno Y; Shino Y; Kondo F; Igarashi N; Wang G; Shimura R; Yamaguchi T; Asano T; Saisho H; Sekiya S; Shirasawa H
    Clin Cancer Res; 2005 Jun; 11(12):4553-60. PubMed ID: 15958641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
    Plattner R; Gupta S; Khosravi-Far R; Sato KY; Perucho M; Der CJ; Stanbridge EJ
    Oncogene; 1999 Mar; 18(10):1807-17. PubMed ID: 10086335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reovirus as an oncolytic agent against experimental human malignant gliomas.
    Wilcox ME; Yang W; Senger D; Rewcastle NB; Morris DG; Brasher PM; Shi ZQ; Johnston RN; Nishikawa S; Lee PW; Forsyth PA
    J Natl Cancer Inst; 2001 Jun; 93(12):903-12. PubMed ID: 11416111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reovirus oncolysis of human breast cancer.
    Norman KL; Coffey MC; Hirasawa K; Demetrick DJ; Nishikawa SG; DiFrancesco LM; Strong JE; Lee PW
    Hum Gene Ther; 2002 Mar; 13(5):641-52. PubMed ID: 11916487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
    Okumura K; Shirasawa S; Nishioka M; Sasazuki T
    Cancer Res; 1999 May; 59(10):2445-50. PubMed ID: 10344756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
    Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
    Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolysis of human ovarian cancers by echovirus type 1.
    Shafren DR; Sylvester D; Johansson ES; Campbell IG; Barry RD
    Int J Cancer; 2005 Jun; 115(2):320-8. PubMed ID: 15688406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oncolytic reovirus against human breast cancer cells.
    Hata Y; Etoh T; Inomata M; Shiraishi N; Nishizono A; Kitano S
    Oncol Rep; 2008 Jun; 19(6):1395-8. PubMed ID: 18497942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.
    Homicsko K; Lukashev A; Iggo RD
    Cancer Res; 2005 Aug; 65(15):6882-90. PubMed ID: 16061672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
    Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
    Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic.
    Loken SD; Norman K; Hirasawa K; Nodwell M; Lester WM; Demetrick DJ
    Cancer Biol Ther; 2004 Aug; 3(8):734-8. PubMed ID: 15197356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.